Bayer is joining the bandwagon of drugmakers getting in on clinical trial transparency, signing on to share some of its data with researchers but stopping well short of industry trailblazers.
Global pharma giant Bayer has inked a three-year deal with the University of Texas' MD Anderson Cancer Center to run clinical trials, matching its investigators with patient-serving oncologists in a deep-seated collaboration.
Shares of the Calabasas, CA-based biotech outfit shot up more than 25% to $42 midmorning on Tuesday after its Monday release on the results. The promise of ATX-101 could make Kythera a buyout target, an analyst from Cowen & Co. noted, and recommended buying the company's shares.
Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
German contract researcher CRS has inked a deal with Bayer, signing up to conduct Phase I and II trials for cardiovascular and women's health treatments.
India's struggles to regulate its booming clinical research industry are well told, but now China could be headed down the same path, as a Beijing court has taken issue with how trial-runners pay compensation to patients.
DKSH, a pharma market-services contractor, has re-upped with Bayer Healthcare to help the drug giant expand its presence in Cambodia, agreeing to handle importation, regulatory clearance and distribution in the Asian nation.
According to CenterWatch's latest Global Investigative Site Relationship survey, clinical trial sites voted Biogen Idec, Forest Laboratories and Bayer the best sponsors, giving them the best marks on 36 relationship attributes.
Bayer Healthcare touted upbeat data from a pair of late-stage studies of an investigational drug targeting chin fat, setting the stage for the giant to step into growing aesthetic treatment market. And the results provide a victory from Kythera, which licensed the injected drug to Bayer for markets outside the U.S. and Canada.
Bayer HealthCare and Onyx Pharmaceuticals won an inside track at the FDA today for their closely-watched cancer drug regorafenib.